In the news release, CCBank Launches Quill Bank to Deliver Banking Expertise to Fintechs, issued 02-Jun-2026 by Capital Community Bank over PR Newswire, we...
WARWICK, NY, June 03, 2026 (GLOBE NEWSWIRE) -- Ozop Energy Solutions, Inc. (OTC: OZSC, the “Company”) today highlighted a major cultural milestone at Unity Electro Fest, a large-scale Canadian electronic music festival in which Varon Wellness, a subsidiary of Varon Corp, holds a strategic ownership interest. Ozop and Varon Corp are currently completing customary pre-closing conditions in connection with the previously announced transaction with OZOP..
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2
BEIJING, China, June 03, 2026 (GLOBE NEWSWIRE) -- Zhihu Inc. (“Zhihu” or the “Company”) (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced its unaudited financial results for the quarter ended March 31, 2026.
TORONTO, June 03, 2026 (GLOBE NEWSWIRE) -- The Greater Toronto Area (GTA) resale housing market tightened in May 2026 compared to last year. Sales increased year-over-year, whereas new listings declined over the same period. As standing inventory has been absorbed, competition between buyers has likely increased in some neighbourhoods. This should see the price trend flatten and ultimately trend upwards in the months ahead.
GENEVA, June 3, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics,...
Appointment marks the next phase of growth across Digital Public Infrastructure, AI-enabled enterprise solutions and international marketsMUMBAI, India, June 3, 2026 /PRNewswire/ -- Protean...
Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.
Eletre X is built for drivers who refuse to compromise - delivering ultimate performance, 1,200+ km of range, and 9-minute charging in a practical hybrid SUV.1 Available to order today, starting from €96,990.